Clinical Trials Browser

Phase 2 × Withdrawn × Docetaxel × Clear all

NCT06392841 2025-10-20

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04183062 2024-11-08

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Phase 2 Withdrawn

Bone Neoplasms, Sarcoma

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05116800 2021-12-07

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04906876 2021-07-28

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02831491 2020-06-09

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02793765 2017-10-30

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

Phase 2 Withdrawn

Neoplasm Metastasis, Prostatic Neoplasms

NCT01087580 2017-03-03

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00598858 2016-12-08

2007-5904

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00964704 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00755157 2015-10-07

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Phase 2 Withdrawn

Neoplasms, Small Cell Lung Carcinoma

NCT01071928 2015-08-19

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT00697060 2015-06-24

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02120118 2015-06-09

Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

NCT00471159 2015-05-04

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Phase 2 Withdrawn

Breast Neoplasms

NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Phase 2 Withdrawn

Breast Diseases, Breast Neoplasms

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01137994 2013-03-13

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01478308 2013-03-06

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00386555 2012-08-09

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00048087 2012-07-31

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT00811031 2012-07-30

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Phase 2 Withdrawn

Prostatic Neoplasms

NCT01229605 2011-12-12

Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms